DBL™ Frusemide

Riik: Uus-Meremaa

keel: inglise

Allikas: Medsafe (Medicines Safety Authority)

Toimeaine:

Furosemide 10 mg/mL; Furosemide 10 mg/mL

Saadav alates:

Hospira NZ Ltd

INN (Rahvusvaheline Nimetus):

Furosemide 10 mg/mL

Annus:

20 mg/2mL

Ravimvorm:

Solution for injection

Koostis:

Active: Furosemide 10 mg/mL Excipient: Sodium chloride Sodium hydroxide Water for injection Active: Furosemide 10 mg/mL Excipient: Sodium chloride Sodium hydroxide Water for injection

Ühikuid pakis:

Ampoule, glass, 50 x 2ml amp, 50 dose units

Klass:

Prescription

Retsepti tüüp:

Prescription

Valmistatud:

Arandy Laboratories Ltd

Näidustused:

DBL™ Frusemide Injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. DBL™ Frusemide Injection is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.

Toote kokkuvõte:

Package - Contents - Shelf Life: Ampoule, glass, 50 x 2ml amp - 50 dose units - 36 months from date of manufacture stored at or below 25°C

Loa andmise kuupäev:

1986-03-04

Toote omadused

              Data Sheet – New Zealand 

Hosp 3.0 
                 1 

DBL™ FRUSEMIDE INJECTION 

NAME OF MEDICINE 
Frusemide 

PRESENTATION 
DBL™ Frusemide Injection is available as a 20 mg/2 mL
injection, prepared with sodium hydroxide giving 
solutions having a pH of about 9. 

USES  
_ACTIONS  _
Frusemide is a potent diuretic. It  inhibits sodium and
chloride absorption in the ascending limb of Henle's 
loop and in both the proximal and distal tubules. 

The high degree of efficacy is due to this unique site
of action. The action on the distal tubule is independent 
of any inhibitory effect on carbonic anhydrase or aldosterone. 

Frusemide may produce a prompt diuresis in cases which have
previously proved resistant to other diuretics. 

Frusemide has no
significant pharmacological actions other than on
renal function. 

_PHARMACOKINETICS, _
_ABSORPTION _
Frusemide is rapidly absorbed from the
gastrointestinal tract.  Absorption
rates in healthy subjects have been 
reported from 60-69% and from 43-46% in patients with end stage
renal failure. 

The
onset of diuresis following intravenous administration is within
5 minutes and somewhat later after 
intramuscular administration. The peak effect occurs within the first half hour. The duration of diuretic effect 
is approximately 2 hours. 

_DISTRIBUTION _
Frusemide is extensively bound to plasma
proteins, mainly to albumin. Plasma concentrations ranging
from 1 
to 400 µg/ml are 91 to 99% bound in healthy individuals. The
unbound fraction averages 2.3 to 4.1% at 
therapeutic concentrations. 

_METABOLISM _
Recent evidence suggests that frusemide glucuronide
is the  only, or at least the major, bio-transformation 
product of frusemide in man. 

_EXCRETION _
In patients with normal renal f